利德曼跌2.12%，成交额7349.64万元，主力资金净流出746.68万元

Group 1 - The core viewpoint of the news is that Lidman has experienced a significant decline in stock price recently, despite a year-to-date increase of over 50% [2] - As of November 24, Lidman's stock price was 7.38 yuan per share, with a market capitalization of 4.015 billion yuan [1] - The company has seen a net outflow of main funds amounting to 746.68 thousand yuan, with large orders showing a notable selling pressure [1] Group 2 - Lidman has recorded a 50.61% increase in stock price year-to-date, but has faced a 20.22% drop in the last five trading days [2] - The company has been listed on the "龙虎榜" (Dragon and Tiger List) four times this year, with the most recent occurrence on August 8 [2] - The main business revenue composition includes 67.84% from in vitro diagnostic reagents, 14.17% from diagnostic instruments, and 4.78% from biochemical raw materials [2] Group 3 - As of November 10, the number of shareholders for Lidman was 33,400, a decrease of 0.93% from the previous period [2] - For the period from January to September 2025, Lidman reported an operating income of 252 million yuan, a year-on-year decrease of 10.49% [2] - The company has distributed a total of 143 million yuan in dividends since its A-share listing, with 5.44 million yuan distributed in the last three years [3]